Glancy Binkow & Goldberg LLP Announces Investigation of Merge Healthcare Incorporated

LOS ANGELES--()--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Merge Healthcare Incorporated (“Merge” or the “Company”) (NASDAQ: MRGE) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Merge concerning the Company’s operations and financial performance and prospects.

Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Merge develops software solutions that enable hospitals, imaging centers, integrated delivery networks, and health information exchanges to create information exchanges within their environments and with other entities worldwide. The Company operates in two segments – Merge Healthcare and Merge DNA (Data and Analytics). The investigation is related to the Company’s January 8, 2014, announcement that Merge is reducing its previously announced non-GAAP subscription backlog totals for the Merge DNA segment for the quarterly periods ended June 30, 2012 through September 30, 2013. According to the Company, an internal review found that a former sales employee in its eClinical business had falsified the existence or amount of certain customer contracts. The Audit Committee of the Company’s Board of Directors then authorized an independent investigation by outside counsel and a forensic accounting firm, which concluded that the former employee had falsified contracts with an apparent value of approximately $5.8 million and $9.4 million in 2012 and 2013, respectively.

If you purchased Merge common stock between February 19, 2013 and January 8, 2014, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

Contact Glancy Binkow & Goldberg LLP if you purchased Merge Healthcare Inc. common stock between February 19, 2013 and January 8, 2014.

Sharing

Contacts

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com